Tokyo Based Eisai News Today

Eisai London, April 2nd, 2024 - CNX Therapeutics Limited (“CNX Therapeutics”), a speciality pharmaceutical company with a portfolio of medicines for the treatment of central nervous system (CNS) disorders and hospital emergencies in over 40 countries worldwide, is pleased to announce that it has suc...

Adjusted earnings for the year will be $14.50 to $15.00 a share, down from the earlier range of $15 to $16, Biogen said in a statement Wednesday.

Cambridge-based Biogen is cutting costs while broadening its focus to replace declining revenue from multiple sclerosis therapies, which made up more than half the drugmaker’s 2022 sales.

An experimental version of Eisai Co.’s Alzheimer’s drug that might be given in patients’ homes exceeded the power of Leqembi, its approved infused formulation, in an early study that could

By Colin Kellaher A pair of late-stage studies of a cancer-drug combination from Merck & Co. and Eisai missed their main goals in patients with certain types of metastatic non-small cell lung...

By Colin Kellaher Merck & Co. and Eisai are ending a late-stage study of the cancer drugs Keytruda plus Lenvima in patients with certain types of...

The couple explains why they agreed to use breakthrough medication, despite serious risks.

Six months after Esai Alzheimer’s disease drug Leqembi received accelerated FDA approval, the agency has awarded the drug full approval. While the agency’s regulatory decision sets precedent for other Alzheimer’s drugs, it also flags serious safety risks.

Eisai gains an option to license a Bliss Biopharmaceutical drug that targets HER2, a cancer protein that has become a hot target for addressing several types of solid tumors. BlissBio could receive up to $2 billion in milestones and other payments.

Follow the StarTribune for the news, photos and videos from the Twin Cities and beyond.